Test Price
2,400 AEDโ Home Collection Available
Liquid Biopsy Cell-Free KRAS Mutation Analysis (cfDNA KRAS) in Dubai UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (for UAE residents).
Test Overview & Methodology
This liquid biopsy detects KRAS gene mutations in circulating tumor DNA (ctDNA) from a simple blood draw, enabling non-invasive cancer monitoring and personalized therapy selections using Droplet Digital PCR (ddPCR) โ the gold standard for ultra-sensitive ctDNA quantification.
| Feature | Our Liquid Biopsy KRAS (ddPCR) | Next-Generation Sequencing (NGS) Panel |
|---|---|---|
| Precision | 99.9% analytical sensitivity for low-frequency mutations (0.01% MAF) | 80โ95% sensitivity; may miss low-allele variants |
| Methodology | Droplet Digital PCR (ddPCR) โ gold standard for ctDNA quantification | Massively parallel sequencing โ broad gene panel |
| Turnaround Time | 5โ7 working days | 10โ14 working days |
| Clinical Actionability | Direct KRAS mutation status for anti-EGFR therapy selection (colorectal, lung) | Broader mutational landscape but often requires orthogonal validation |
| Cost in UAE | 2,400 AED | 4,000โ7,000 AED |
Physician Insight & Safety Protocols
โAs a Consultant Medical Genetics, I emphasize that this liquid biopsy test detects actionable KRAS mutations with high sensitivity. However, results must be integrated with clinical history, imaging, and other biomarkers. A negative result does not exclude malignancy; a positive mutation may guide targeted therapy decisions. Always consult your healthcare provider before altering treatment.โ
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Safety Advisory
โ ๏ธ Medication Advisory: Do not discontinue prescribed medication without consulting your doctor. This test is not a substitute for clinical evaluation.
Exclusion Criteria & Emergency Red Flags
- Test is not indicated for patients currently undergoing surgery or planning surgery within the next 72 hours.
- Not applicable for pregnant individuals or those planning to travel abroad (as laboratory confirmation may be delayed).
- Do not proceed if you have an active severe infection (e.g., sepsis) or uncontrolled acute medical condition.
- Seek immediate emergency care if you experience: chest pain, difficulty breathing, heavy bleeding, or signs of stroke after blood collection.
Patient FAQ & Clinical Guidance
1. What is the KRAS liquid biopsy test?
Itโs a non-invasive blood test that detects KRAS gene mutations in circulating tumor DNA for personalized cancer care. This test allows oncologists to monitor treatment response and detect resistance mutations without repeated tissue biopsies.
2. How should I prepare for the test?
A doctorโs prescription is mandatory; avoid heavy meals and strenuous exercise 2 hours before blood collection. No fasting is required, but inform the phlebotomist of any blood-thinning medications you are taking.
3. When will I get my results and what do they mean?
Results are available within 5โ7 working days and include a clinical interpretation by our oncology geneticists. A positive KRAS mutation indicates eligibility for specific targeted therapies or resistance to anti-EGFR drugs; a negative result may support alternative treatment plans.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Healthcare Compliance
This laboratory service is fully compliant with the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All home collections follow strict cold-chain logistics and data encryption standards to protect your health information.
Clinical & Logistical Metadata
| Test Name | Liquid Biopsy Cell-Free KRAS Mutation Analysis (cfDNA KRAS) |
| Price (AED) | 2,400 AED |
| Turnaround Time | 5โ7 working days |
| Sample Type / Matrix | Plasma (from peripheral blood) |
| Methodology Used | Droplet Digital PCR (ddPCR) |
| ICD-10-CM Code | C80.0 (Malignant neoplasm, primary site unknown), C18.9, C34.9 |
| LOINC Code | 88233-7 (KRAS gene mutations found in Plasma) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians